Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow enhancements. JENA, (Germany), SHANGHAI, (China), | 27 ...

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the fourth quarter and full year ended December 31, 2024. All figures included ...

Aligne Wealth Advisors Investment Management (AWAIM) proactively manages risk and return opportunities as markets evolve. This forward-looking approach recently led to strategic portfolio adjustments ...

Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow JENA, Germany and SHANGHAI, Feb. 26, 2025 /PRNewswire/ ...

The device offers a shortened procedure time and efficient, effective SMILE for patients with myopia, with or without ...

ZEISS Medical Technology announced today that the National Medical Products Administration (NMPA) in China has approved the ...

A significant factor in the company's growth is the launch of the Visumax 800 in China. However, JPMorgan is skeptical about the demand for this higher-priced premium product, given the subdued demand ...

Shares of Carl Zeiss Meditec AG (ETR:AFX) dropped 6% today after the company reported its first-quarter revenues, which showed a slight increase of 1.2% versus the Vara consensus but were coupled with ...

Carl Zeiss Meditec reports slight revenue growth of +3.2% in the first three months of fiscal year 2024/25, driven by order entry and order backlog recovery ...

The good response to the new products, the approval of our VISUMAX ® 800 refractive laser system for the Chinese market and the general recovery in order entry and order backlog give us ...